#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Short stature homeobox gene mutation Hormone-dependent prostate cancer Diffuse large B-cell lymphoma refractory Dermatomyositis Vaginal cancer Mantle cell lymphoma refractory Neoplasm malignant Congenital disorder of glycosylation Glioblastoma Stargardt's disease Oesophageal atresia Desmoplastic small round cell tumour Adenovirus infection Pouchitis Penile cancer More trials…

    Learn about Rare Diseases

    CADASIL – Life with Disease Hypereosinophilic syndrome – Treatment Antithrombin III deficiency – Trials in Disease Familial haemophagocytic lymphohistiocytosis Haemophilia Arterial tortuosity syndrome – Life with Disease Gaucher’s disease type III – Treatment Waldenstrom’s macroglobulinaemia Cystic fibrosis – Life with Disease Gaucher’s disease type I – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Perindopril Arginine Hydroxocobalamin Mk-1200 Dfv890 Danicamtiv Avapritinib Ethambutol Acetylcysteine Pyridoxine Hydrochloride Bp Arachis Hypogaea Flour Bi 685509 Lutropin Alfa Clofazimine Noradrenaline Tartrate Anhydrous Cyclophosphamide Digoxin Mk-1167 L-Lysine Acetate Pertuzumab IM-101 More therapies…

    Learn about Your Condition

    Skin bacterial infection Cardiac sarcoidosis Huntington's disease Cleft lip and palate Thrombolysis Papulopustular rosacea Bone marrow failure Palpitations Transplantation complication Oral herpes Myelofibrosis Dry eye Spinal cord injury Urethral stenosis BRAF gene mutation More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Asklepios Kliniken Hamburg GmbH

Asklepios Kliniken Hamburg GmbH

Eissendorfer Pferdeweg 52, Heimfeld, Hamburg, 21075, Germany

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Trastuzumab Deruxtecan and Rilvegostomig for Patients with Advanced HER2-positive Biliary Tract Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • HER2 positive biliary tract cancer
    Investigated Drugs:
    • Cisplatin
    • Durvalumab
    • Gemcitabine
    Austria Belgium Czechia France Germany Italy +4

  • Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • BNT327
    • Carboplatin
    • Paclitaxel
    Belgium Bulgaria France Germany Hungary Italy +3

  • Study on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Azacitidine
    • Ivosidenib
    • Venetoclax
    Austria Belgium Denmark Estonia Finland France +8

  • Study of Arfolitixorin, 5-Fluorouracil, Oxaliplatin, and Bevacizumab for Patients with Metastatic Colorectal Cancer

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • ARFOLITIXORIN
    • Calcium Folinate
    Germany

  • Study on the Safety of Self-Infusion Therapy with Human Alpha1-Proteinase Inhibitor for Patients with Severe Alpha-1 Antitrypsin Deficiency

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Human Alpha1-Proteinase Inhibitor
    Germany

  • Study Comparing Amivantamab and Chemotherapy Versus Cetuximab and Chemotherapy for Patients with Advanced Colorectal Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Amivantamab
    • Cetuximab
    Belgium France Germany Hungary Italy The Netherlands +3

  • Study Comparing Elranatamab, Daratumumab, and Lenalidomide with Daratumumab, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Elranatamab
    • Bortezomib
    • Daratumumab
    Austria Belgium Czechia Denmark Finland France +6

  • Study comparing prophylactic versus selective surfactant (poractant alfa, phospholipid fraction) administration in preterm infants with respiratory distress syndrome aged 25-30 weeks

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Neonatal respiratory distress syndrome
    Investigated Drugs:
    • Poractant Alfa
    • Phospholipid Fraction, Bovine Lung
    Germany

  • Study on Zanidatamab with Cisplatin and Gemcitabine for Advanced HER2 Positive Biliary Tract Cancer Patients

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Zanidatamab
    • Cisplatin
    • Durvalumab
    Belgium Czechia Finland France Germany Italy +4

  • Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Ifinatamab Deruxtecan
    • Topotecan
    Austria Belgium Czechia France Germany Greece +7
Previous Page
1 2 3 4 5 6 … 13
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!